Matching
Match the treatment with its target.
Premises:
ipilimumab
brentuximab
ibritumomab
lirilumab
nivolumab
elotuzumab
vemurafenib
Responses:
CD30
CD20
BRAF
programmed death 1 (PD-1)
CTLA-4
CD319
HLA-C-specific inhibitory KIRs
Correct Answer:
Premises:
Responses:
ipilimumab
brentuximab
ibritumomab
lirilumab
nivolumab
elotuzumab
vemurafenib
Premises:
ipilimumab
brentuximab
ibritumomab
lirilumab
nivolumab
elotuzumab
vemurafenib
Responses:
Related Questions
Q39: The efficacy of treating bladder cancer is
Q40: A tumor-associated antigen normally expressed only in
Q41: Which cytokines are associated with tumor-induced suppression
Q42: Proteins not expressed on normal cells but
Q43: Which of the following is a mechanism
Q44: Which of the following describe types of
Q45: Which of the following are true for
Q46: One of the side effects of treating
Q47: Match the infectious agent with the
Q49: Match the term with its description.
Unlock this Answer For Free Now!
View this answer and more for free by performing one of the following actions
Scan the QR code to install the App and get 2 free unlocks
Unlock quizzes for free by uploading documents